Weight loss pills, Ozempic's big fan, and Merck's skin cancer drug: Pharma news roundup
Plus, Wegovy users keep the weight off, and Johnson & Johnson says goodbye to Tylenol
It may take a weight loss pill for Eli Lilly to finally meet demand for its popular anti-obesity medications, according to the pharma giant’s top leader on weight loss drugs. Denmark’s prime minister, Mette Frederiksen, called the Ozempic “fantastic” and said she was “huge fan” at a parliamentary debate. And Merck announced Monday that it’s pulling the plug on its trial of an experimental combination treatment for skin cancer.
Check out those stories and more pharmaceutical news highlights from this week.
2 / 8
People who depend on daily insulin shots may soon have welcome news: a new experimental drug could cut their treatments down from daily doses to weekly ones. Eli Lilly announced positive result on Thursday of its phase-3 clinical trails (QWINT-2 and QWINT-4) for its weekly insulin efsitora. Trial results showed that the long-acting insulin was just as effective as traditional daily doses.
3 / 8
Swiss pharma giant Roche posted positive results on Thursday of its phase-1 clinical trail for its experimental weight loss drug CT-388. Roche said that patients taking CT-388 lost an average 18.8% of weight after 24 weeks on the drug.
4 / 8
Danish pharma giant Novo Nordisk, the maker of the popular diabetes and weight loss drugs Ozempic and Wegovy, has a prominent admirer in its home country. Denmark’s Prime Minister, Mette Frederiksen, called the medications “fantastic” and said she was “huge fan” at a parliament debate, Bloomberg reported.
5 / 8
It may take a weight loss pill for Eli Lilly to finally meet demand for its popular anti-obesity medications, according to Eli Lilly’s top leader on weight loss drugs. “Even if we take the combined supply of our [medications] and the competition, it’s not sufficient to meet the needs of 110 million Americans,” President of Lilly Diabetes and Obesity Patrik Jonsson told Quartz in an interview.
6 / 8
Two new analyses of the longest clinical trial of semaglutide — the active ingredient in Wegovy — have shed some light on the long-term effects of the popular weight loss medication.
7 / 8
Kenvue, the maker of popular consumer health brands like Tylenol and Listerine, announced Monday that Johnson & Johnson is selling its remaining stake in the company. The reversal comes about a year after the healthcare giant spun off its consumer health business into Kenvue.
8 / 8
Merck announced Monday that it is pulling the plug on its phase 3 trial of an experimental combination treatment for skin cancer after side effects of the medication led patients to drop out of the study.